Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 101.8 EUR 0.3%
Market Cap: 12B EUR
Have any thoughts about
Biomerieux SA?
Write Note

Gross Margin
Biomerieux SA

55.7%
Current
57%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.7%
=
Gross Profit
2.1B
/
Revenue
3.8B

Gross Margin Across Competitors

Country FR
Market Cap 12B EUR
Gross Margin
56%
Country US
Market Cap 199.5B USD
Gross Margin
56%
Country US
Market Cap 190.6B USD
Gross Margin
67%
Country US
Market Cap 140.3B USD
Gross Margin
64%
Country US
Market Cap 133.7B USD
Gross Margin
69%
Country IE
Market Cap 104.5B USD
Gross Margin
65%
Country US
Market Cap 65.8B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.3B USD
Gross Margin
79%
Country CN
Market Cap 308.3B CNY
Gross Margin
64%
Country US
Market Cap 36.4B USD
Gross Margin
41%
No Stocks Found

Biomerieux SA
Glance View

Market Cap
12B EUR
Industry
Health Care

In the world of clinical diagnostics, bioMérieux SA emerges as a formidable player, weaving together a tapestry of innovation, precision, and reliability. Founded in 1963 by Alain Mérieux, the company has its roots deeply embedded in Lyon, France, where a legacy of scientific prowess meets a global vision. bioMérieux specializes in in vitro diagnostics, creating a broad array of products and solutions that essentially serve as the medical community’s early warning systems. Their expertise spans across fields like microbiology, immunoassays, and molecular biology, where they craft diagnostic kits and automated instruments that empower healthcare providers to detect and prevent diseases with remarkable accuracy. By tapping into a robust network of research and development, bioMérieux collaborates with hospitals, laboratories, and public health organizations worldwide to address both routine and critical diagnostic needs. At the heart of bioMérieux’s business is its razor-sharp focus on infectious diseases, a sector that has seen accelerated growth in recent years, particularly with the advent of global health challenges such as the COVID-19 pandemic. The firm generates revenue through the sale of its diagnostic solutions and related services, offering comprehensive testing systems that include reagents and consumables, maintenance contracts, and training for laboratory professionals. Their continuous investment in innovation allows them to expand their product portfolio and tailor solutions to the evolving needs of the healthcare industry. By maintaining a pulse on global health trends and investing in cutting-edge technologies, bioMérieux not only secures its market position but also plays a crucial role in strengthening global public health infrastructure.

BIM Intrinsic Value
109.78 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.7%
=
Gross Profit
2.1B
/
Revenue
3.8B
What is the Gross Margin of Biomerieux SA?

Based on Biomerieux SA's most recent financial statements, the company has Gross Margin of 55.7%.